Dutch Oncology COVID-19 consortium:Outcome of COVID-19 in patients with cancer in a nationwide cohort study

Aim of the study: Patients with cancer might have an increased risk for severe outcome of coronavirus disease 2019 (COVID-19). To identify risk factors associated with a worse outcome of COVID-19, a nationwide registry was developed for patients with cancer and COVID-19. Methods: This observational cohort study has been designed as a quality of care registry and is executed by the Dutch Oncology COVID-19 Consortium (DOCC), a nationwide collaboration of oncology physicians in the Netherlands. A questionnaire has been developed to collect pseudonymised patient data on patients' characteristics, cancer diagnosis and treatment. All patients with COVID-19 and a cancer diagnosis or treatment in the past 5 years are eligible. Results: Between March 27th and May 4th, 442 patients were registered. For this first analysis, 351 patients were included of whom 114 patients died. In multivariable analyses, age ≥65 years (p < 0.001), male gender (p = 0.035), prior or other malignancy (p = 0.045) and active diagnosis of haematological malignancy (p = 0.046) or lung cancer (p = 0.003) were independent risk factors for a fatal outcome of COVID-19. In a subgroup analysis of patients with active malignancy, the risk for a fatal outcome was mainly determined by tumour type (haematological malignancy or lung cancer) and age (≥65 years). Conclusion: The findings in this registry indicate that patients with a haematological malignancy or lung cancer have an increased risk of a worse outcome of COVID-19. During the ongoing COVID-19 pandemic, these vulnerable patients should avoid exposure to severe acute respiratory syndrome coronavirus 2, whereas treatment adjustments and prioritising vaccination, when available, should also be considered

Bioequivalence of Liposome-Entrapped Paclitaxel Easy-To-Use (LEP-ETU) Formulation and Paclitaxel in Polyethoxylated Castor Oil: A Randomized, Two-Period Crossover Study in Patients With Advanced Cancer

Clinical Pharmacy and Toxicolog

Hydrogen bonding in the bleu copper site.: A resonance Raman study

Microbial BiotechnologyBiological and Soft Matter PhysicsMacromolecular Biochemistr

Changes in body weight during various types of chemotherapy in breast cancer patients

Background & aims: Weight gain is a common problem for breast cancer patients treated with chemotherapy. It increases the risk of several comorbidities and possibly cancer recurrence. We assessed whether weight gain depends on the type of chemotherapy. Methods: In a retrospective study among 739 breast cancer patients, we assessed whether change in body weight during chemotherapy differed between types of chemotherapy. Information about weight, clinical and personal factors was retrieved from medical records of breast cancer patients treated with chemotherapy between 2001 and 2010 in 4 different hospitals. Results: Body weight information was complete in n=483 patients (66%). There was substantial between-patients variability in weight change during chemotherapy: within the upper quintile of weight change, median weight gain was+6kg, while in the bottom quintile median weight loss was of-3kg. Adjusted multivariate regression analysis showed that change in weight differed between types of chemotherapy: women treated with anthracyclines+taxanes gained+0.9kg (95%CI 0.1, 1.7) more than women treated with anthracyclines only. This differential change in weight was no longer statistically significant after taking into account that regimens with anthracyclines+taxanes have a longer duration than regimens with anthracyclines only. Conclusion: There was more weight gain among patients treated with anthracyclines+taxanes than among patients treated with anthracyclines-only. This is partly explained by the longer duration of regimes with anthracyclines+taxanes. © 2013 European Society for Clinical Nutrition and Metabolism

Addition of zoledronic acid to neoadjuvant chemotherapy is not beneficial in patients with HER2-negative stage II/III breast cancer: 5-year survival analysis of the NEOZOTAC trial (BOOG 2010-01)

Surgical oncolog